Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.

The m6A modification is a critical factor in the development of both benign and malignant female reproductive system diseases. By modulating the expression of genes that are linked to malignancies, m6A modification influences the growth and metastasis of cervical cancer (CC), endometrial cancer (EC), choriocarcinoma (CCA), and ovarian cancer (OC) (Fig. 3 , Table 1 ). In the context of benign disorders, m6A modification is implicated in PCOS, primary Ovarian Insufficiency (POI), spontaneous abortion (SA), gestational diabetes (GDM), and preeclampsia (PE) through a variety of underlying mechanisms (Fig. 4 ). Consequently, comprehensive investigations of m6A modification mechanisms not only enhance the understanding of the pathogenesis of these diseases but also offer robust support for clinical decision-making. Fig. 3 Effect of m6A modification on gynecological malignancies. In cervical cancer, m6A modification-associated transcripts consist of mRNA (ACIN1, CENPK, E2F3, GAS5, MYC), circCCDC134, and miR-503-5P. In ovarian cancer, m6A modification-associated transcripts consist of mRNAs (VGLL1, DDR2, Snail, PLAGL2), CircRAB11 and its target-related miRNAs, and lncRNA RMRPs. In endometrial cancer, m6A modification-associated transcripts consist of mRNA (PEG10, PDGFRB, E2F3, FENDRR, IRS1), Circcchd7, miR-3147, and Linc00958. In choriocarcinoma, transcripts associated with m6A modification include HIF1AN, miR-935, and miR-21-5p. Table 1 The roles of m6A in gynecological cancer. Disease m6A regulator Expression Target Mechanism Ref Cervical cancer METTL3 Up IRF5, PPP6C Increase PPP6C expression level and promote the progression of CC. [ 310 ] METTL3 Up ACIN1 Enhance the stability of ACIN1 mRNA and accelerate the proliferation and migration of CC. [ 452 ] METTL3 Up HK2 Targeting the 3ʹ UTR of HK2 mRNA, enhances HK2 stability and the Warburg effect. [ 312 ] IGF2BP2 Up MYC Promote aerobic glycolysis, proliferation and metastasis of CC cells. [ 314 ] ALKBH5 Down SIRT3, ACC1 Promote SIRT3 instability, down-regulate ACC1 level, and inhibit tumorigenesis and lipid metabolism. [ 315 ] METTL14 Up TRIM11, PHLPP1 Enhance TRIM11 mRNA stability, PHLPP1 is reduced by ubiquitination, and activated AKT signaling pathway. [ 316 ] YTHDF2 Up AXIN1 Regulates tumor EMT and cisplatin chemotherapy sensitivity. [ 320 ] FTO Up BMP4 BMP4 is upregulated in an m6A-dependent manner, activating the Hippo/YAP1/TAZ signaling pathway and promoting tumor invasion. [ 321 ] ALKBH5 Up circCCDC134 Regulates MYB expression, activates HIF1A transcription, and exerts oncogenic effects. [ 323 ] Ovarian cancer METTL3 Up AXL Upregulated AXL to boost EMT. [ 332 ] METTL3 Up VGLL1, HMGA1 VGLL1 interacts with TEAD4 to activate HMGA1, which in turn activates the Wnt/β-catenin signaling pathway and promotes EMT. [ 333 ] METTL14 Down TROAP Enhance TROAP expression levels and accelerate OC aggressiveness. [ 334 ] WTAP Up MAPK, AKT Regulates MAPK/AKT signaling pathways, promotes cell proliferation and migration. [ 429 ] KIAA1429 Up ENO1 Stabilize ENO1 mRNA in an m6A-dependent manner to promote tumor progression and glycolysis. [ 337 ] HNRNPA2B1 Up miR-30c-5p miR-30c-5p downregulates the level of HNRNPA2B1, thereby inhibiting OC cell proliferation. [ 338 ] YTHDF1 Up EIF3C Enhances EIF3C translation through m6A modification and promotes protein synthesis, leading to OC proliferation and metastasis. [ 339 ] YTHDC1 Down PIK3R1, GANAB Affect N-glycosylation biosynthesis, inhibit the development of OC. [ 341 ] FTO Down SNAI1 Inhibits tumor cell EMT and slows down tumor growth and metastasis. [ 345 ] Endometrial cancer METTL14/ METTL3 Down PHLPP2, mTORC2 Activates the AKT signaling pathway, promotes tumor proliferation. [ 350 ] YTHDF2 - YBX2, HSPA6 YTHDF2 interacts with YBX2 in an m6A-dependent manner to co-regulate HSPA6 mRNA stability. [ 353 ] YTHDF2 Up IRS1 Downregulated IRS1 expression, inhibit IRS1/AKT signaling pathway and EC proliferation. [ 354 ] IGF2BP1 Up PEG10, p16, p18 Enhance PEG10 mRNA stability, inhibit the expression of p16 and p18, promote EC proliferation and regulate tumor cell cycle and cancer progression. [ 355 ] WTAP/ IGF2BP3 Down EGR1, PTEN Promotes the formation of EC stem cell properties and the development of tumors. [ 359 ] IGF2BP3 Up E2F3, LINC00958 Upregulated E2F3 expression and promoted the progression of EC. [ 361 ] ALKBH5 Up IGF1R Promotes the translation of IGF1R protein and EC proliferation. [ 363 ] Choriocarcinoma METTL3 Up GJA1, miR-935 Promote the maturation of miR-935, inhibit the expression of GJA1, and promote the proliferation and migration of CCA. [ 367 ] METTL3 Up HIF1AN, HIF1A, VEGF, miR-21-5p Activate HIF1A/VEGF pathway to promote EMT of CCA. [ 368 ] Fig. 4 Effects of m6A modification on benign gynecological and obstetric diseases. Numerous gynecological disorders, such as endometriosis (EMT), polycystic ovary syndrome (PCOS), premature ovarian failure (POI), spontaneous abortion (SA), gestational diabetes mellitus (GDM), and preeclampsia (PE), have been found to be influenced by m 6 A. In the aforementioned disorders, we describe modifications in the m 6 A methylation-associated enzymes METTL3, METTL14, RBM15, YTHDC1, YTHDF2, IGF2BP2, FTO, and ALKBH5. In cervical cancer, m6A modification-associated transcripts consist of mRNA (ACIN1, CENPK, E2F3, GAS5, MYC), circCCDC134, and miR-503-5P. In ovarian cancer, m6A modification-associated transcripts consist of mRNAs (VGLL1, DDR2, Snail, PLAGL2), CircRAB11 and its target-related miRNAs, and lncRNA RMRPs. In endometrial cancer, m6A modification-associated transcripts consist of mRNA (PEG10, PDGFRB, E2F3, FENDRR, IRS1), Circcchd7, miR-3147, and Linc00958. In choriocarcinoma, transcripts associated with m6A modification include HIF1AN, miR-935, and miR-21-5p. The roles of m6A in gynecological cancer. Numerous gynecological disorders, such as endometriosis (EMT), polycystic ovary syndrome (PCOS), premature ovarian failure (POI), spontaneous abortion (SA), gestational diabetes mellitus (GDM), and preeclampsia (PE), have been found to be influenced by m 6 A. In the aforementioned disorders, we describe modifications in the m 6 A methylation-associated enzymes METTL3, METTL14, RBM15, YTHDC1, YTHDF2, IGF2BP2, FTO, and ALKBH5. CC is a public health issue that poses an imperative threat to the reproductive health of women and is the fourth most widespread form of cancer in women worldwide. Cervical malignancy is primarily caused by an insistent infection with high-risk HPV. However, the prevention of cervical cancer has been demonstrated to be effective through regular screening and prophylactic vaccination [ 308 , 309 ]. m6A-related regulators are crucial to the progression and development of CC. METTL3 regulates the stability and translation of the catalytic subunit of protein phosphatase 6 (PPP6C) through the m6A modification of mRNA, thereby influencing the downstream transcription factor interferon regulatory factor 5 (IRF5) activity and collaboratively regulating the malignant biological behavior of cervical cancer [ 310 ]. METTL3 and IGF2BP3 also regulate the expression level of apoptotic chromatin condensation inducer 1 (ACIN1). The specific mechanism by which ACIN1 induces CC invasion may be accomplished through the interaction of these two m6A regulators, thereby up-regulating the expression level of ACIN1 [ 311 ]. The role of regulators related to m6A has garnered increasing attention in tumor metabolism, including glycolysis and lipid metabolism. A study by Wang et al. discovered that METTL3 targets and increases the m6A modification of hexokinase 2 mRNA, while recruiting YTHDF1 to recognize the m6A modification sites on the transcript, enhancing mRNA stability and thus promoting the occurrence of CC and glycolysis [ 312 ]. METTL14 and IGF2BP3 have the potential to maintain the stability of stearoyl-CoA desaturase (SCD) mRNA through the m6A system, which can influence lipid metabolism processes and provide new therapeutic strategies for CC [ 313 ]. Additionally, numerous investigations have successively documented the precise mechanism by which IGF2BP2, ALKBH5, and other compounds regulate the metabolism of cervical malignancies via the m6A mechanism [ 252 , 314 , 315 ]. Zhang et al. discovered that METTL14 and IGF2BP1 mediate the m6A modification of TRIM11 (an E3 ubiquitin ligase) mRNA, thereby increasing its stability and expression levels. The upregulation of TRIM11 promotes the degradation of the PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), which in turn contributes to the progression of CC [ 316 ]. In cervical cancer, the activation of the PI3K/Akt pathway is frequently associated with tumor aggressiveness and poor prognosis [ 317 ]. Li et al. demonstrated that METTL14-mediated m6A modification regulates the stability of FTH1 mRNA, influencing the PI3K/Akt signaling pathway and thereby inhibiting the progression of cervical cancer [ 318 ]. YTHDF1, a reading protein, identifies and binds the m6A modification on RANBP2 mRNA, thereby improving its translational efficiency and facilitating the development of CC [ 19 ]. According to a study investigated by Tao et al., YTHDF2 initially recognizes the m6A modification of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) mRNA, that is mediated by METTL3. Subsequently, it collaborates with the RNA helicase DDX6 to further enhance RNA degradation and decrease NR4A1 expression, thereby propelling CC progression [ 319 ]. Another study also demonstrated that YTHDF2 plays a role in regulating the expression of the target gene AXIN1, which indirectly influences the activity of the Wnt/β-catenin signaling pathway. This, in turn, modulates the EMT progression in cervical tumors and affects the sensitivity to chemotherapeutic agents [ 320 ]. Huang etal.‘s research in cervical carcinogenesis proved that FTO accelerates tumor progression by eliminating m6A methylation from Bone Morphogenetic Protein 4 (BMP4) mRNA. This mechanism results in a rise in BMP4 protein expression levels, which then inhibits downstream Hippo signaling pathways and activates critical effector molecules [ 321 ]. Furthermore, m6A regulators are also implicated in cervical cancer-related mechanisms through ncRNAs. HPV16 E7 gene encodes virus-derived circRNA (circE7) that generates the E7 oncoprotein and is linked to cervical cancer. Related research has indicated that the development and progression of CC may be influenced by the mutual regulation of circE7 and m6A modifications [ 322 ]. An investigation accomplished by Liang et al. revealed that the demethylase ALKBH5 was capable of removing the m6A modification of circCCDC134 and improving its stability. Subsequently, circCCDC134 acted carcinogenic in CC by sponge-like adsorbing miR-503-5p and stimulating the expression of hypoxia-inducible factor 1a (HIF-1α) [ 323 ]. Huang et al. reported that the m6A modification on precursor miR-193b could facilitate its processing into mature miR-193b through METTL3. Further down-regulation of miR-193b encourages the proliferation and invasion of cervical cancer cells by targeting and promoting CCND1-encoding cyclin D1 (CyclinD1) mRNA expression [ 324 ]. YTHDF2 and ALKBH5 interact with the lncRNA Growth Arrest-Specific 5 Antisense 1 (GAS5-AS1) to improve the stability of the tumor suppressor gene Growth Arrest-Specific 5 (GAS5) RNA through a m6A-dependent mechanism, thereby delaying CC invasion and metastasis [ 325 ]. By modulating the stability and enhancing the biological function of LRRC75A-AS1, IGF2BP1 contributes to the progression of CC by suppressing the ubiquitinated degradation of the NLR family pyrin domain 3 (NLRP3) inflammasome, which is carried out by the ubiquitin ligase SYVN1 [ 326 ]. In addition, FTO mediates the m6A methylation modification of lncRNA HOXC13-AS and enhances its stability, thereby upregulating frizzled protein class receptor 6 (FZD6) and further activating Wnt/β-catenin signaling. This process results in the EMT and invasion of CC [ 327 ]. Other studies have also detailed the different processes through which m6A modification is implicated in the modulation of CC [ 325 , 328 , 329 ]. In general, m6A modification takes part in cervical cancer through multiple pathways, but the specific mechanism of action needs further exploration. OC is a gynecological tumor that is high in invasiveness and mortality. OC often presents with non-specific first symptoms, most cases are realized at an advanced stage, and about 70% of cases recurrent at a later stage [ 330 , 331 ]. Ovarian carcinogenesis is facilitated by m6A regulators through a range of mechanisms. METTL3 expression levels in ovarian cancer displayed an up-regulation trend [ 332 ]. A study discovered that the down-regulation of METTL3 resulted in changes in m6A modification levels, which in turn regulated the stability and translation of oncogene protein kinase B (AKT) mRNA, reduced the phosphorylation activity of AKT protein, and inhibited the progression of OC by down-regulating downstream target cyclin D 1 (CCND1) expression levels [ 17 ]. METTL3 could also facilitate the maturation of pri-miR-126-5p and mediate its m6A modification. As a result, miR-126-5p targets and upregulates downstream tensin homolog PTEN expression levels, thereby activating the PI3K/Akt/mTOR signaling pathway and contributing to the progression of OC [ 18 ]. By maintaining the stability of estigial Like Family Member 1 (VGLL1) and upregulating its expression levels through the m6A system, METTL3 and IGF2BP2 further activate the VGLL1/High Mobility Group AT-hook 1 (HMGA1)/β-catenin axis, resulting in OC metastasis [ 333 ]. The impacts of METTL14-associated m6A regulatory mechanisms on OC is complex and may exhibit both pro- and tumor suppressor potential, dependent upon the specific molecular and cellular context [ 334 , 335 ]. The significant role of m6A-dependent related mechanisms mediated by WTAP, RBM15, KIAA1429, and HNRNP in the development and progression of OC has been confirmed by numerous studies [ 163 , 336 – 338 ]. A study by Liu et al. found that YTHDF1 is responsible for the m6A modification of EIF3C mRNA, which increases its translational efficacy and contributes to the progression of OC [ 339 ]. YTHDF2 contributes to the progression of OC by mediating the m6A modification of BMF mRNA and promoting its degradation, thus affecting the process of apoptosis [ 340 ]. Conversely, YTHDC1, an additional YTH family reading protein, functions as an OC suppressor. The precise mechanism of action is primarily regulated by the PIK3R1/STAT3/GANAB axis [ 341 ]. A study accomplished by Wang et al. on ovarian cancer suggested that IGF2BPs have the capacity to bind the m6A modification on circNFIX, thereby increasing its stability. The overexpression of circNFIX is implicated in tumor malignancy by up-regulating the expression of the miR-647 target gene interleukin-6 receptor (IL-6R) and activating the downstream JAK1/STAT3 signaling pathway [ 342 ]. Meanwhile, this process regulates the programmed death ligand 1 (PD-L1) expression to achieve OC-associated immune escape. The TGF-β signaling pathway is believed to be implicated in drug resistance in tumors. One study suggested that the TGF-β pathway may regulate the expression of MDR1 mRNA by modulating the m6A methylation process of RBM15, thereby influencing the chemoresistance of ovarian cancer cells and impacting the prognosis of OC [ 343 ]. Additionally, Huang et al. found that FTO-dependent m6A methylation modification is associated with cisplatin resistance in ovarian cancer, although the specific signaling pathways and underlying mechanisms involved in this process remain to be fully elucidated [ 344 ]. Furthermore, The expression levels of snail homologous protein 1 (SNAI1) are reduced by FTO in a m6A-IGF2BP2-dependent manner, thereby inhibiting the invasiveness and metastasis of EOC [ 345 ]. According to a study conducted by Lv et al., the demethylase ALKBH5 is responsible for the m6A demethylation of lncRMRP, which in turn promotes the expression level of RMRP and facilitates the development of OC [ 346 ]. FTO and ALKBH5 demethylation may affect the expression of genes associated with autophagy in OC and contribute to tumor proliferation and invasion [ 172 , 347 ]. Follicle-stimulating hormone (FSH) has been demonstrated to be involved in the promotion of EMT in OC during specific instances and is associated with the malignancy of OC. An investigation accomplished by Xu et al. investigated the precise mechanism of this theory. FSH increased the expression of ALKBH5, which removed the m6A modification from Snail mRNA. This resulted in higher Snail expression in a m6A-dependent manner. The process led to reduced expression of E-cadherin and promoted mesenchymal genes like N-cadherin, which contributed to OC metastasis [ 348 ]. Multiple mechanisms of signaling involved in the development of OC are regulated by the mentioned multiple m6A regulators in a m6A-dependent manner. Nevertheless, there are significant unresolved questions regarding the role of m6A modification in OC. EC is an imminent threat to the reproductive health of women, as it is prevalent among Perimenopause and postmenopausal women [ 349 ]. Within the past few years, its prevalence has increased. m6A modification plays a critical role in EC. Liu et al. proposed in a study on EC that METTL3-mediated m6A modification revealed a propensity to be down-regulated, which in turn facilitated the progression of EC by stimulating the AKT pathway and regulating the expression levels of downstream target proteins [ 350 ]. The aforementioned mechanisms that drive the malignant effects of EC are also affected by METTL14 mutations. Nevertheless, two additional studies reported conflicting results [ 351 , 352 ]. Due to this, the biological function of METTL3 in EC remains uncertain. YTHDF2 and YBX2 have the capacity to collaborate on heat shock protein family A (Hsp70) member 6 (HSPA6) mRNA to regulate HSPA6 expression by modulating its stability, which regulates the survival and progression of cancer cells [ 353 ]. Additionally, research by Hong et al. has verified that YTHDF2 decreases EC invasiveness by targeting and downregulating the expression of insulin receptor substrate 1 (IRS1) via the m6A system [ 354 ]. The recognition and binding of m6A-modified paternally expressed gene 10 (PEG10) mRNA by IGF2BP1 promotes the expression of PEG10 protein by increasing its stability, which promotes the progression of EC [ 355 ]. Numerous investigations confirmed the precise mechanism by which IGF2BP family proteins induce EC invasion [ 356 – 358 ]. Wang et al. proposed that WTAP and IGF2BP3 may collaboratively regulate the expression of the downstream early growth response factor-1 (EGR1)/PTEN axis through m6A methylation. This regulatory mechanism plays a crucial role in modulating the characteristics and progression of EC stem cells [ 359 ]. Furthermore, the m6A modification of ncRNAs has been identified as a critical factor in the mechanisms of EC development. For instance, circCHD7 attracts the reader protein IGF2BP2 to bind and enhance the stability of platelet-derived growth factor receptor β (PDGFRB) mRNA through m6A modification. This process further activates the downstream JAK/STAT signaling pathway by upregulating PDGFRB expression and affecting EC progression [ 360 ]. In a study of endometrial cancer investigated by Wang et al., it was discovered that LINC00958 attaches to IGF2BP3, which in turn promotes the stability of E2F3 mRNA and boosts the expression of E2F3 gene levels through a m6A methylation mechanism. Consequently, it promotes the invasiveness of EC [ 361 ]. FTO activates the Wnt signaling pathway, which in turn leads to EC invasion, by inhibiting HOXB13 mRNA degradation via a m6A modification-dependent pathway [ 362 ]. ALKBH5, another demethylase, further facilitates the activation of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway by improving the stability and translational efficiency of IGF1R mRNA by targeting m6A modification [ 363 ]. This mechanism results in the proliferation and invasion of EC. In addition, ALKBH5 is a factor which regulates the expression of tumor stemness genes(e.g., SOX2) and impacts the pathogenicity of EC [ 250 ]. The invasiveness of EC is influenced by a variety of m6A regulators, which regulate and target the expression of key genes and the activity of signaling pathways. In the future, more studies will identify the rigorous mechanism of m6A modification in the advancement of EC. CCA is a rare and highly aggressive malignant tumor that arises from prenatal trophoblastic tissue. It has a very low occurrence rate but carries a nearly 100% mortality rate unless specific chemotherapeutic drugs are used [ 364 ]. The field of m6A modification in CCA is undergoing accelerated development. The most of current investigations on the association between CCA and m6A modification involve mechanisms related to ncRNAs. Lu et al. conducted a study which demonstrated that miR-373-3p, an EMT inhibitor, inhibited CCA invasion by downregulating the TGFβ signaling pathway [ 365 ]. MiR935 has been reported to be meaningfully upregulated in CCA tissues [ 366 ]. Additionally, a study discovered that METTL3 induces the maturation of miR-935 and mediates its m6A modification, thereby increasing its expression level. Following this, miR-935 targets and inhibits the production of the gap junction protein GJA1, which causes CCA cells to proliferate and invade [ 367 ]. Also, Ye et al. confirmed that METTL3 enhances the level of miR-21-5p through the m6A mechanism, which activates the hypoxia-inducible factor asparagine hydroxylase (HIF1A) and further up-regulates the expression of pro-angiogenic factor (VEGF). This increases the blood supply to tumor cells, thereby driving CCA growth and metastasis [ 368 ]. Studies on how CCA interacts with other m6A regulators are not available at this time. In the future, we anticipate that additional research will reveal the comprehensive mechanism of m6A modification in CCA, thereby generating novel concepts for the diagnosis and treatment of this kind of disease. Adenomyosis is a common gynecological condition which is characterized by the invasion of the myometrium by endometrial glands and stroma, resulting in myometrial hypertrophy. Dysmenorrhea and irregular vaginal hemorrhage are the primary characteristics of the disease, greatly affect the quality of life of those impacted [ 369 ]. According to published research, m6A regulators may regulate immune responses and cell adhesion during the development of adenomyosis [ 370 ]. While there is a scarcity of research on m6A modification in adenomyosis, there is some sign that it may be influential in the endometrium and associated diseases. Zhai et al. confirmed that the METTL3-mediated m6A modification was capable of targeting and regulating the expression of critical genes, including insulin-like growth factor 1 (IGF1) and the detoxifying enzyme DDT, that influenced the invasiveness of adenomyosis. This was achieved by analyzing endometrium-associated gene expression profiles in patients with adenomyosis in the GEO database [ 370 ]. EMT is a multipart condition that is initiated by abnormal growth-related mechanisms in the endometrium, some of which are presently unknown [ 371 ]. According to a study accompanied by Li et al., bioinformatics analysis indicated that six m6A regulators (METTL3, YTHDF2, YTHDF3, FTO, HNRNPC, and HNRNPA2B1) were differentially expressed among ectopic endometrium and controls. Among them, the growth and invasion of ectopic endometrial cells may be regulated by changes in the expression of HNRNPA2B1 and HNRNPC, which may influence immune mechanisms in endometriosis [ 372 ]. Furthermore, another study showed that the down-regulation of methylase METTL3 further impacted DGCR8-mediated splicing processes by reducing the m6A modification level of pri-miR126. This decrease in m6A modification level led to a decrease in the generation of mature miRNA126, which consequently facilitated the migration and invasion of endometriosis [ 373 ]. The aforementioned studies offer preliminary insights into the investigation of m6A modification and the correlation between endometriosis and adenomyosis. To cultivate a thorough comprehension of the precise mechanisms of the interaction between the two, additional in vitro verification in the future is required. POI may be influenced by the activity of m6A regulators in regulating germ cell metabolism and function. Cao et al. discovered that the secretion of interleukin 1β (IL-1β) by theca cells was upregulated by decreased levels of m6A modification, which in turn promoted the development of POI by knocking down METTL3 [ 374 ]. Pathogenic variants in the reading protein YTHDC2 may influence the normal progression of the meiotic process and contribute to the development of POI [ 375 ]. FTO-mediated m6A demethylation has the potential to improve the stability of circBRCA1, which subsequently binds miR-642a-5p and exerts a sponge-like effect. This prevents the interaction of circBRCA1 with the transcription factor (FOXO1) and contributes to the prevention of POI [ 376 ]. This conclusion was substantiated by Ding et al. [ 377 ]. Furthermore, it has been demonstrated that chemical toxicants, including cyclophosphamide (CTX) and 4-vinylcyclohexene diepoxide (VCD), can impair ovarian function and induce POI. In a rat model of VCD-induced ovarian dysfunction, ALKBH5 acts on YAP mRNA in a m6A-dependent mechanism to further upregulate YAP expression and affect ovarian function [ 378 ]. In a human granulosa cell model and a mouse model of POI, investigators discovered that the m6A modification levels in cells or tissues increased substantially in a concentration-dependent manner after CTX treatment, thereby driving the progression of POI [ 379 ]. The direction and focus of future research are the specific mechanisms or relevant targets implicated in m6A affecting POI. Hyperandrogenism, insulin resistance, and ovulatory dysfunction are frequently encountered in PCOS [ 380 ]. The pathogenesis of PCOS is significantly influenced by the m6A methylation modification of mRNA. It has been demonstrated that the activity and protein of insulin-related signal transduction pathways, such as the PI3K/AKT pathway, appear to influence the pathogenesis of PCOS in murine PCOS models through the m6A mechanism [ 15 ]. Nevertheless, specific studies are still in the preliminary phases of development. In addition, various studies have previously shown a correlation between FTO gene abnormalities and the mechanisms that lead to the development of PCOS [ 381 , 382 ]. FTO expression is positively correlated with androgen levels, and androgen excess is one of the significant manifestations of PCOS. Xue et al. accomplished a study that verified the precise mechanism of FTO-mediated m6A demethylation modification in PCOS-induced androgen excess. Through the m6A mechanism, FTO enhances the stability of key enzymes involved in androgen synthesis, including CYP17A1 and HSD3B2, and up-regulates their expression levels, thereby contributing to androgen synthesis. The inhibition of FTO contributes to a decrease in the expression of these enzymes and the androgen receptor (AR), which in turn reduces the AR/AKT signaling activity and effectively reduces androgen production and secretion, thereby improving the hyperandrogenic state [ 383 ]. Another study suggested that FTO could also contribute to insulin resistance in PCOS by removing the m6A modification from the membrane-associated protein FLOT2 (Flotillin-2) mRNA. This would reduce its degradation, increase its stability, and up-regulate FLOT2 expression levels [ 384 ]. Moreover, a study of m6A modification in luteinized granulosa cells (GC) from PCOS patients found that YTHDF2 mediated m6A modification of Forkhead Box O3 (FOXO3) mRNA and participated in its degradation in GC from controls group. However, this mechanism was absent in PCOS group, indicating that there is dysregulation of FOXO3 transcription by m6A regulators in PCOS, which may affect pathological development of PCOS [ 385 ]. In the future, these discoveries will offer novel concepts for elucidating the fundamental mechanism of PCOS pathogenesis. SA is a frequent complication of pregnancy, and its mechanism is intricate. Numerous researches have verified the association between m6A methylation levels and miscarriage [ 386 , 387 ]. Huang et al. hypothesized that the m6A modification of Zinc Finger and BTB Domain Containing 4 (ZBTB4) mRNA by METTL3 may be implicated in recurrent miscarriage-associated mechanisms by regulating ZBTB4 expression [ 388 ]. Another investigation determined that the reading protein HnRNPC regulates the expression of 5-methyltetrahydrofolate homocysteine methyltransferase (MTHFR) through the m6A mechanism and may induce recurrent miscarriage [ 389 ]. The correlation between abortion and benzene exposure was progressively confirmed. Benzo (a) pyrene-7,8-dihydrodiol-9,10-epoxy (BPDE) is a group of chemicals that have reproductive toxicity. They can impact trophoblast function through a variety of pathways, which may result in abortion. According to a study conducted by Xu et al., the methylase METTL14 was upregulated by BPDE exposure. Thus, increased its stability and promoted its expression level by adding m6A modification to lnc-HZ01 and MXD1 mRNA. Consequently, a positive self-feedback loop mechanism was established between the two, which hindered trophoblast proliferation and resulted in abortion [ 390 ]. In addition, two additional studies have shown that the up-regulation of lnc-HZ14 [ 230 ] and lncRNA-HZ09 [ 391 ] is a result of the up-regulation of BPDE exposure, respectively. These mechanisms are related to abortion pathogenesis. Multiple mechanisms are employed by the demethylase ALKBH5 to induce abortion-associated diseases. Li et al. hypothesis that ALKBH5 could impede trophoblast invasion by increasing the stability of CYR61 mRNA and mediating m6A modification [ 231 ]. Another study, which utilized bioinformatics analysis, indicates that the dysregulation of the VEGF signaling pathway may result from ALKBH5 overexpression. This dysregulation impacts the function of macrophages in the endometrium and promotes recurrent spontaneous abortion [ 392 ]. In contrast, Zheng et al. discovered that ALKBH5 is capable of up-regulating the expression levels of transcription factors SMAD1 and SMAD5 through the m6A demethylation mechanism, thereby promoting trophoblast viability and preventing spontaneous abortion [ 393 ]. Abnormalities of the maternal-fetal interface are frequently linked to spontaneous abortion. FTO-mediated m6A modification processes have been reported to be crucial for the preservation of normal maternal-fetal interfaces. The downregulation of FTO has the potential to result in maternal-fetal-related morbidity, including spontaneous abortion [ 394 ]. In research concerning the pathogenesis of unexplained abortion, investigators have also discovered that the FTO-related m6A modification mechanism regulates the MEG3-TGF-β signaling pathway, thereby influencing chorionic invasiveness and inducing abortion [ 395 ]. Investigating the relationship between the mechanism of abortion and m6A will aid in comprehending the molecular underpinnings of abortion and may yield novel clinical preventive and therapeutic strategies. As previously mentioned, the mechanisms by which m6A regulators regulate the invasion and migration of placental trophoblasts are involved. However, the progression of PE may be influenced by aberrant trophoblastic invasion. Related research has shown a strong correlation between the development of PE and the upregulation of m6A modification levels [ 208 , 396 ]. In contrast, there are also indications that the levels of m6A modification are downregulated in PE. Complex mechanisms associated with the METTL3-myosin light chain kinase (MYLK) axis and the WTAP/IGF2BP1/high mobility group nucleosome binding domain 3 (HMGN3) axis are implicated in this discovery [ 228 , 397 ]. Further investigation of its impact on m6A modification levels will assist in the identification of the pathogenesis of PE. In a study conducted by Chen, it was suggested that METTL3 and YTHDF2 reduce the level of transmembrane BAX inhibitor 6 (TMBIM6) by regulating the m6A modification of TMBIM6 mRNA and promoting its degradation. This process results in the dysfunction of trophoblasts and the development of PE [ 398 ]. Newly published research has also discovered that METTL3 is implicated in the progress of PE by influencing the iron apoptotic mechanism of trophoblasts. It regulates the m6A modification of Acyl-CoA Synthase Long Chain Family Member 4 (ACSL4) mRNA through a specific mechanism [ 399 ]. Furthermore, in HTR-8/SVneo cells, the up-regulation of METTL14 alters the stability and translation of FOXO3a mRNA by increasing m6A modification. This results in increased FOXO3a expression, which in turn leads to PE development [ 400 ]. One study discovered that the overexpression of the methylase RBM15 reduced CD82 expression and facilitated trophoblastic invasion and PE development by increasing the levels of m6A modification, promoting YTHDF2 recognition and binding to CD82 mRNA, and enhancing its degradation [ 401 ]. In contrast, ALKBH5 has the potential to alleviate the pathological process of PE by increasing the expression level of PLAC8 by eliminating the m6A modification on placenta-specific 8 (PLAC8) mRNA [ 402 ]. The ncRNAs are also regulated by the m6A regulator to influence trophoblast function in PE through a variety of mechanisms. Wang et al. confirmed that METTL3 mediates the m6A modification of lncRNA HOXD-AS1 and maintains its stability. Subsequently, the up-regulated HOXD-AS1 recruits miR-135a and exerts a sponge-like effect, relieving its inhibition of the target gene anti-apoptotic protein β-repein transducat-containing protein (β-TRCP) mRNA. This contributes to the upregulation of β-TRCP expression, stimulation of the NF-κB signaling pathway, and an impact on PE development [ 403 ]. Similarly, the circSETD2/miR-181a-5p/Myeloid Cell Leukemia 1 (MCL1) axis, which is mediated by METTL3, is also implicated in the development of PE [ 404 ]. METTL14 and IGF2BP3 may also be responsible for the regulation of circPAPPA2 m6A methylation stability and the enhancement of its expression, which can impact the progression of PE and placental function [ 405 ]. Finally, the regulation of angiogenesis-related gene expression in trophoblasts may be facilitated by the IGF2BP2-mediated m6A modification of linc01116 RNA, which offers a novel perspective on the development of PE [ 406 ]. The manipulation of insulin sensitivity, inflammatory response, placental function, and cellular metabolism is the fundamental mechanism of m6A modification in GDM [ 407 – 409 ]. One study suggests that METTL3-dependent m6A modification enhances the stability of hsa_circ_0072380, potentially influencing the pathogenesis of GDM by regulating pathways or gene expression associated with these factors [ 410 ]. Furthermore, Ning et al. elucidated the pivotal role of m6A modification in placental development in GDM, demonstrating that FTO regulates the fusion process of trophoblast cells by modulating the stability and expression of SIK1 mRNA [ 411 ]. A study that utilized GEO data indicated that m6A-modified LINC00667 may be involved in the development of GDM by modulating the expression of downstream GDM-related target genes in response to the recognition and binding of YTHDF3 [ 412 ]. This conclusion must, however, be verified in in vivo or in vitro models. In high glucose-cultured HTR8/SVneo cells, METTL14 inhibits FOXO1 expression, enhances trophoblast function, increases downstream miR-497-5p expression levels, and mediates XIST silencing through the m6A mechanism, thereby impeding the progression of GDM [ 413 ]. Chen et al. discovered that chemokine ligand 5 (CCL5) levels were generally higher in GDM patients. Conversely, METTL14 possibly influenced the progression of GDM by mediating m6A modification of CCL5 and affecting its stability, which may have resulted in the promotion of proliferation, migration, and apoptosis of trophoblasts [ 414 ]. In addition, Fang et al. discovered that RBM15 regulates CLDN4 expression through m6A modification, which subsequently affects hepatic glucose and lipid metabolism in the progeny of GDM mice, resulting in insulin resistance [ 415 ]. Currently, there are insufficient studies on the function of m6A modification in GDM regulation, and the precise mechanism is unclear. Therefore, further studies are necessary. Future research should aim to validate these preliminary findings through more sufficient in vivo and in vitro experiments, alongside large-scale, multicenter clinical studies, to further elucidate the biological functions and underlying mechanisms of m6A modification in GDM. Such studies will provide a more robust and reliable foundation for a comprehensive understanding of the role of m6A modification in the pathogenesis and progression of GDM.

How does m6A modification specifically regulate the balance between immune tolerance and response in the maternal-fetal microenvironment, and what are the long-term implications for both maternal and fetal health? What are the precise molecular mechanisms by which m6A modification influences the progression of various gynecological cancers, and how can this knowledge be leveraged to develop targeted therapies? Given the recent advancements in m6A detection technologies, what new insights can be gained about the role of m6A in non-malignant gynecological conditions such as endometriosis and polycystic ovary syndrome? Can m6A modification patterns serve as reliable biomarkers for the diagnosis, prognosis, and treatment response monitoring in gynecological diseases, and what validation is needed to implement them in clinical practice? How do environmental factors and lifestyle choices impact m6A methylation patterns in the context of female reproduction and gynecological health, and what preventive strategies can be developed based on this knowledge? How does m6A modification specifically regulate the balance between immune tolerance and response in the maternal-fetal microenvironment, and what are the long-term implications for both maternal and fetal health? What are the precise molecular mechanisms by which m6A modification influences the progression of various gynecological cancers, and how can this knowledge be leveraged to develop targeted therapies? Given the recent advancements in m6A detection technologies, what new insights can be gained about the role of m6A in non-malignant gynecological conditions such as endometriosis and polycystic ovary syndrome? Can m6A modification patterns serve as reliable biomarkers for the diagnosis, prognosis, and treatment response monitoring in gynecological diseases, and what validation is needed to implement them in clinical practice? How do environmental factors and lifestyle choices impact m6A methylation patterns in the context of female reproduction and gynecological health, and what preventive strategies can be developed based on this knowledge?

m6A Modification in Female Reproduction: The role of N6-methyladenosine (m6A) in female reproduction is an emerging field, with evidence suggesting its involvement in oocyte maturation, embryonic development, and placental function, which are crucial for maternal-fetal health. Epigenetic Regulation in Gynecological Diseases: m6A modification has been implicated in various gynecological diseases, including cervical cancer, ovarian cancer, endometrial cancer, and choriocarcinoma, potentially affecting their progression and treatment outcomes. Technological Advances in m6A Detection: Recent developments in high-throughput sequencing and other detection technologies have expanded our ability to study m6A modifications at single-base resolution, offering new opportunities for understanding the mechanisms of gene regulation. m6A’s Impact on Immune Cells: The influence of m6A on immune cells within the maternal-fetal microenvironment, such as dendritic cells, natural killer cells, and macrophages, suggests a significant role in modulating immune tolerance and responses during pregnancy. Clinical Implications and Challenges: The potential of m6A as a biomarker and therapeutic target and biomarker in gynecological diseases is evident, but the complexity of its regulatory mechanisms and the need for a comprehensive understanding of its role in different pathological contexts present challenges for clinical application. m6A Modification in Female Reproduction: The role of N6-methyladenosine (m6A) in female reproduction is an emerging field, with evidence suggesting its involvement in oocyte maturation, embryonic development, and placental function, which are crucial for maternal-fetal health. Epigenetic Regulation in Gynecological Diseases: m6A modification has been implicated in various gynecological diseases, including cervical cancer, ovarian cancer, endometrial cancer, and choriocarcinoma, potentially affecting their progression and treatment outcomes. Technological Advances in m6A Detection: Recent developments in high-throughput sequencing and other detection technologies have expanded our ability to study m6A modifications at single-base resolution, offering new opportunities for understanding the mechanisms of gene regulation. m6A’s Impact on Immune Cells: The influence of m6A on immune cells within the maternal-fetal microenvironment, such as dendritic cells, natural killer cells, and macrophages, suggests a significant role in modulating immune tolerance and responses during pregnancy. Clinical Implications and Challenges: The potential of m6A as a biomarker and therapeutic target and biomarker in gynecological diseases is evident, but the complexity of its regulatory mechanisms and the need for a comprehensive understanding of its role in different pathological contexts present challenges for clinical application.

The m6A modification mechanism in various of gynecological tumors has been progressively elucidated, which is anticipated to promote the creation of innovative therapeutic strategies and enhance the prognosis of patients. Furthermore, the potential of m6A modifiers as biomarkers for the early diagnosis and prognosis of cancer is increasingly recognized and investigated. While traditional tumor markers (e.g., CA125, HE4,SCC) and diagnostic methods (e.g., HPV detection, TCT) have played an important role in the early detection and monitoring of gynecological cancers, their clinical applicability is constrained by limitations such as low sensitivity, poor specificity, and insufficient capacity for dynamic monitoring. Future advancements in quantifying and localizing specific m6A modification levels and loci within blood exosomal RNA and tissue mRNA hold promise for overcoming these challenges. Such approaches could provide powerful tools for the early and accurate diagnosis, biomarker discovery, and the personalization of treatment strategies for gynecological malignancies. However, the clinical application of m6A modification in early detection remains largely in the basic research phase, with no existing clinical studies to date. Thus, further standardization and rigorous clinical validation will be necessary to translate these findings into clinical practice. In CC, m6A methylation levels are significantly correlated with cancer progression and survival. The levels of ZC3H13, YTHDF1, and YTHDC1 expression in cervical squamous cell carcinoma (CESC) were found to significantly correlate with the prognosis of CESC by bioinformatics analysis [ 416 ]. These proteins may also be useful targets for cancer therapy. According to Wang et al., the aforementioned conclusions were partially corroborated by the findings of a biological analysis study of CC patients in the GEO and TCGA databases. The study revealed that RBM15 is a prognostic biomarker in CC, and ZC3H13 may impact overall survival (OS) in CC patients [ 417 ]. Therefore, further mechanistic investigations are necessary to validate these conclusions in the future. A study confirmed that YTHDF1 induces the expression of RANBP2 (RAN-binding protein 2) through a m6A-dependent mechanism, thereby facilitating CC metastasis [ 19 ]. The m6A modification of low-density lipoprotein receptor-related protein 6 (LRP6) mRNA is mediated by YTHDF3, which subsequently promotes the expression of LRP6 protein and activates downstream signaling pathways. This process is responsible for the invasion of CC and the metastasis of lymph nodes [ 418 ]. YTHDFs proteins may have a significant impact on CC treatment, as suggested by relevant studies. A study on the mechanism of CESC resistance revealed that FTO, through eliminating m6A alteration on β-catenin mRNA, increasing its stability, and up-regulating expression levels, might boost patient chemoresistance and lessen the lethal effect of chemotherapeutic medicines on cancer cells [ 419 ]. Centromere protein K (CENPK) is also a contributing factor to recurrence and drug resistance in CC. A study discovered that the Wnt/β-catenin signaling pathway was activated by methylase ZC3H13, which increased the level of CENPK mRNA and mediated the m6A methylation modification process. This process resulted in the progression of CC and development of chemoresistance [ 420 ]. In cancer management, early detection of potential recurrence, assessment of patient response to treatment, and prediction of prognosis are crucial for optimizing therapeutic strategies and improving patient survival and quality of life. Therefore, dynamic monitoring of m6A modifier expression levels, coupled with the development of predictive models based on these markers, could provide a more comprehensive evaluation of treatment responses, recurrence risks, and long-term prognoses. Additionally, clinicians could stratify patients into high-risk and low-risk groups based on m6A modification factor expression, which would offer a foundation for personalized treatment plans. Currently, most in vivo and in vitro studies primarily focus on the expression levels of m6A modification-related molecules and their correlation with patient prognosis. However, further large-scale cohort studies are required to validate these findings, ensuring a robust clinical translation of m6A methylation modifications in reproductive system diseases. The results of numerous bioinformatics-related researches have indicated that m6A modifier regulators have significant prognostic potential in OC [ 421 – 428 ]. A study based on OC patients in the TCGA database revealed that high expression of WTAP, YTHDF1/2/3, FTO, and ALKBH1/5, while low expression level of METTL14 may be associated with poor prognosis in OC [ 425 ]. Li et al.‘s study indicates that VIRMA, IGF2BP1, and HNRNPA2B1 may be correlated to the prognosis of OC. The risk prediction model has been found to be effective based on the aforementioned conclusions. In addition, the investigators employed the miRbase database to screen upstream miRNA targets of the aforementioned genes and discovered that miR-196b-5p may target IGF2BP1, modulate the expression level of downstream PTEN protein, and lead to OC progression [ 422 ]. Zhu et al. additionally demonstrated the predictive role of KIAA1429 and YTHDC2 in OC [ 426 ]. Nevertheless, these findings are only suitable for use as a preliminary reference, as they are not supported by confirmatory in vitro experiments. Yu et al. conducted an experimental study on high-grade serous ovarian cancer (HGSOC) that confirmed elevated WTAP expression as a poor predictor of HGSOC [ 429 ]. This research partially corroborates the conclusions of Han et al. [ 425 ]. Sun et al. also discovered that ALKBH5 overexpression may be involved in pertinent mechanisms that mediate OC lymph node metastasis [ 430 ]. A study conducted by Ye et al. was innovative in that it combined machine learning algorithms to screen m6A modification-related lncRNAs in serous ovarian cancer (SOC) and establish a predictive model (m6A-LRM). The study found that METTL3 down-regulation may be involved in regulating RP11-508M8.1 (one of the selected lncRNAs) and promoting OC cell invasion [ 428 ]. The model demonstrated a high degree of predictive accuracy for the treatment effect of SOC and OS in the subsequent validation trial. Platinum medications serve as the foundation of initial OC treatment. A study on cisplatin resistance in OC patients discovered that METTL3 increased the stability of lncRNA RHPN1 antisense RNA 1 (lncRNA RHPN1-AS1) in a m6A-dependent mechanism. This, in turn, resulted in increased cisplatin resistance in OC patients by upregulating the downstream PI3K/AKT pathway [ 431 ]. Another study also demonstrated that the METTL3/YTHDF2 axis also downregulates interferon-inducible RNA helicase 1 (IFFO1) expression by mediating the m6A modification of IFFO1 mRNA and promoting its degradation, leading to cisplatin resistance and metastasis in ovarian cancer [ 432 ]. Furthermore, Yuan et al. verified that the RBM15 expression level can predict paclitaxel resistance in OC patients. The specific mechanism is affected by the transforming growth factor-β (TGF-β)/RBM15/multidrug resistance protein 1 (MDR1) axis, in which RBM15 regulates MDR1 expression through the m6A mechanism, thereby affecting the effect of chemotherapy [ 343 ]. Specific mechanisms of ALKBH5 [ 433 ], FTO [ 434 ], and YTHDF1 [ 248 , 435 ] in OC cisplatin resistance, as well as METTL3 [ 436 ] in OC carboplatin resistance, have also been reported in numerous studies. Given the m6A regulators previously mentioned, there is an increasing interest in the investigation of targeted agents that are linked to OC resistance. For instance, AE-848 has the capacity to function as a targeted agent for OC therapy by destabilizing IGF2BP3-targeted mRNA, thereby impeding the growth and progression of OC cells [ 437 ]. Sulfonamides (Sul) are potential targets for OC therapy and may influence the process of apoptosis through the METTL3-mediated m6A mechanism [ 438 ]. As prospective biomarkers and therapeutic targets in OC, FTO and ALKBH5 may be implicated in PARP inhibitor (PARPi)-related biological mechanisms [ 439 ]. However, research on targeted therapies related to m6A modification has yet to reach the clinical trial stage. Furthermore, most existing studies rely on animal and cellular models, which do not adequately reflect the complexity of human tumors, particularly in terms of the tumor microenvironment, immune response, and treatment response. The intricate nature of m6A modification mechanisms, combined with tumor heterogeneity and individual variability, makes it challenging for current models to fully capture the dynamics of tumor growth and metastasis. Moreover, existing studies lack an in-depth exploration of long-term tumor progression and the mechanisms underlying drug resistance, which significantly restricts the clinical translation and application of m6A modification research findings. Future research should concentrate on this topic in order to elucidate the molecular mechanisms which may aid in the development of clinical treatments. The regulatory mechanisms of pertinent prognostic biomarkers in EC are also influenced by the m6A modification and its regulators. Based on CpG sites in the m6A regulator, specific prognostic prediction models have been developed in related studies that are effective in foreseeing the prognosis of patients with EC [ 440 ]. Zhai et al. hypothesized that FTO, YTHDF1 and RBM15 are ‌important‌ factors in the prognosis of EC patients in a study that utilized the TCGA dataset of EC patients [205]. An additional experimental study conducted recently also verified that the elevated METTL3, METTL14, FTO, HNRNPC, and HNRNPA2B1 expression levels are associated with a shorter OS in EC patient [ 351 ]. In addition, Zhan et al. discovered that METTL3 and YTHDF2 are involved in the m6A modification process of NLRC5 mRNA, which upregulates its stability and inhibits degradation. This results in an increase in NLRC5 expression levels, a reduction in NLRC5-mediated immune surveillance, and a participation in EC progression [ 441 ]. The IGF2BP1 is involved in the process of EC cell metastasis, as it binds to and promotes the expression and accumulation of TRKB protein in a m6A-dependent manner [ 358 ]. Moreover, two studies accomplished by Shi [ 442 ] et al. and Shan [ 443 ] et al. demonstrated a correlation between the expression levels of m6A-related lncRNA and the survival of ECs, as well as immune-related mechanisms. Consequently, it is conceivable that the m6A regulators listed above may be promising targets in the development of EC, and the inhibitors or activators that are generated may have potential regulatory effects on the treatment and prognosis of EC patients. Limited research has been conducted on the topic of EC treatment and resistance. It has been reported that METTL14 and YTHDF2 are indirectly implicated in the progression of iron death by influencing the methylation process of protein arginine methyltransferase (PRMT) through the m6A mechanism. However, the aforementioned processes are impeded by PRMT inhibition, which enhances the sensitivity of endometrial cancer cells to iron death and offers a novel perspective on EC treatment and drug resistance research [ 444 ]. In summary, clinicians will be able to detect and treat gynecological malignancies at an early period, thereby enhancing the survival rate of patients, by conducting a thorough analysis of the high-risk factors associated with their occurrence and development. Additionally, treatment of other female reproductive system diseases and m6A-related mechanisms. In a rat model of PCOS, Zhang et al. found that Cangfu Daotan Decoction (CDD) methylation of m6A decreased the activity of the Wnt/β-catenin pathway, thereby improving the recovery of ovarian function [ 445 ]. Another study suggested that butyric acid supplementation could alleviate the symptoms of PCOS by inhibiting the expression of METTL3 and reducing the stability and expression of FOSL2 mRNA. This would down-regulate the expression of NLRP3 and further decrease the expression of downstream inflammatory factors [ 446 ]. There are inflammatory factors that contribute to the development of ovarian senescence, whereas melatonin has a potent antioxidant effect. Zhu et al. demonstrated that melatonin mitigates the decline in ovarian function by regulating the expression of the m6A regulator YTHDF2 and reducing its mediated mRNA degradation, further blocking the MAPK-NF-κB signaling pathway and achieves anti-inflammatory objectives [ 447 ]. Interesting, it has been shown that melatonin is also essential for the protection of pregnancy by modulating inflammatory and apoptosis-related pathways through the m6A mechanism [ 448 ]. Finally, Chen et al. confirmed that m6A expression was significantly elevated in trophoblasts of GDM patients with obesity compared to non-obese individuals. Hesperidin was able to indicate its potential role in the treatment of GDM by participating in the regulation of autophagy and m6A methylation levels [ 449 ]. In the future, more comprehensive research is needed to investigate the specific mechanism of m6A modification in the treatment of female reproductive system diseases. The development of drugs targeting m6A modification regulators represents a cutting-edge frontier in the field of RNA epigenetics. To date, clinical trials of related therapeutics have progressed relatively slowly, with the majority of researches still in the basic research or early-phase clinical trial stages. Currently, m6A-modifying regulators under investigation include METTL3 inhibitors such as STM2457 [ 450 ] and STC-15, as well as FTO inhibitors like MO-I-500 and R-2-hydroxyglutaric acid (R-2HG) [ 451 ], which have shown potential for treating various solid tumors and related diseases. These compounds are anticipated to emerge as novel therapeutic agents in the RNA epigenetics domain. Notably, a clinical trial ( NCT05584111 ) evaluating the METTL3 inhibitor STC-15 in advanced solid tumors is underway, with preliminary results expected by 2024. With an increasing understanding of the molecular mechanisms underlying m6A modification and the continuous evolution of drug development technologies, it is projected that more m6A-targeted therapies will advance into clinical trials, potentially offering new treatment avenues for obstetric and gynecological diseases.

The m6A modification is a highly prevalent methylation modification in RNA that is critical for cellular physiology and pathology. In this study, we present a comprehensive overview of m6A-related regulators and their biological function-related mechanisms, the development history of m6A detection methods, the various roles that m6A modification plays in the female reproductive system, and their possible connections to associated diseases. Additionally, the m6A modification has a multifaceted effect on the development of related maladies and the health of female reproductive systems. It regulates t the maturation and development of reproductive cells, the synthesis and signal transduction of reproductive hormones, the maintenance of maternal-fetal microenvironment homeostasis, and the mechanisms related to embryonic development. This perspective provides obstetricians and gynecologists with a fresh understanding of the diseases in question. Currently, the primary bottlenecks and challenges in the field of m6A modification include the unclear and complex regulatory mechanisms, the experimental model is not fully representative, and the limited accuracy of detection technologies. Although m6A modification has shown potential in the occurrence, progression, and targeted therapy of various diseases, its clinical application as a biomarker remains in the early stages. There is also a lack of m6A-targeted drugs or therapeutic strategies, and numerous technical and biological hurdles must still be overcome for successful clinical translation. The gap between basic research and clinical application is hindered by both technical and practical obstacles. To address these challenges, it is essential for basic research to focus on standardizing m6A detection methods and improving their accuracy. Additionally, collaboration with clinical practice should be strengthened through large-scale, multi-center studies to validate findings and facilitate the integration of m6A modification research into clinical settings. Moreover, future research should explore the interactions between m6A modification and other epigenetic modifications, such as DNA methylation and histone modifications, particularly in gynecological cancers. Investigating how these epigenetic changes synergistically or mutually regulate gene expression and cellular function will provide deeper insights into the mechanisms driving disease initiation and progression, thereby offering a more comprehensive theoretical foundation for early diagnosis, prognosis evaluation, and targeted therapies. This study has several limitations. Many of the studies related to m6A modification and obstetric and gynecological diseases included in this review have small sample sizes and primarily focus on cell lines and small animal models, which are not supported by large-scale clinical data. While these experimental models provide essential insights into the biological mechanisms of m6A modification, they may not fully capture the complexity and diversity of human diseases. Additionally, small sample studies are prone to statistical biases that could affect the reliability of the findings. Therefore, future research should prioritize the collection of clinical samples, particularly through multi-center, large-scale clinical cohort studies, to more comprehensively assess the clinical relevance of m6A modification in the onset, progression, and prognosis of diseases of the female reproductive system. In addition, while relevant studies have highlighted the potential role of m6A modification in diseases of the female reproductive system, particularly cancer, the underlying molecular mechanisms and the complex regulatory networks involved remain not fully elucidated. One example is that the scarcity of researches on the regulatory mechanisms of m6A modification on immune cells and reproductive cells in various pathological conditions. Additionally, the regulatory mechanisms of the m6A regulator are complex, as they may serve distinct functions in various diseases. Moreover, the regulatory mechanism of the m6A mechanism in specific gynecological diseases (e.g., PCOS, endometriosis, GDM, etc.) has not been thoroughly examined. Therefore, future research should focus on elucidating the detailed molecular mechanisms of m6A methylation modification in regulating gene expression, and investigate how these processes influence the beginning and progression of female reproductive system diseases. Additionally, it is crucial to explore strategies for enhancing the specificity and precision of targeted therapies, addressing potential drug resistance issues that may arise during treatment. This will provide theoretical support for the development of individualized treatment plans and facilitate the translation of m6A modification mechanisms into clinical practice, ultimately advancing therapy in clinical settings.

Epitranscriptomics refers to the dynamic and reversible process of chemically changing several kinds of RNA molecules, including mRNAs and non-coding RNAs. These modifications play a critical role in governing RNA functionality and determining its fate, as well as influencing the gene expression process [ 1 , 2 ]. The discovery of over 170 RNA alterations in various organisms has led to an increasing number of studies being conducted to elucidate their precise pathways in the development of disease [ 2 ]. The primary epitranscriptomic modifications consist of N6-methyladenosine (m6A) [ 3 ], N1-methyladenosine (m1A) [ 4 ], 5-methylcytidine (m5C) [ 5 ], and pseudouridine (Ψ) [ 6 ]. Out of all the chemical modifications in eukaryotic messenger RNAs, m6A is regarded as the most prevalent [ 3 ]. The particular mechanism of m6A modification in RNA involves the insertion of a methyl group (CH3) at the N6 position of adenine A in the RNA molecule. As an essential element of the epigenetic, m6A modification dynamically regulates multiple aspects of gene expression, containing RNA splicing, stability, translation, and degradation. Furthermore, m6A modification interacts closely with other epigenetic mechanisms, including DNA methylation and histone alterations, collectively contributing to the precise regulation of gene expression. DNA methylation is typically correlated to gene silencing, while m6A modification and histone modifications primarily center on post-transcriptional regulation. The coordinated interplay of these three modifications plays an essential role in biological processes, regulating cellular fate, immune responses, and the development of various diseases [ 7 , 8 ]. Women’s reproductive health is a crucial component of societal progress [ 9 ]. Currently, due to the fast-paced socio-economic progress, there is a heightened global focus on reproductive health. However, a significant number of women continue to experience various reproductive health issues, including gynecological cancer, pregnancy-related ailments, infertility, gynecological chronic diseases, and more. These conditions can have detrimental effects on women’s physical health, family life, and economic well-being, and in severe cases, they can even be life-threatening [ 10 , 11 ]. Hence, comprehending the mechanism and target of associated diseases is crucial for resolving issues pertaining to clinical treatment. The study of epigenomics has steadily confirmed the connection between m6A modification and the physiological and pathological processes in the female reproductive system [ 12 ] (Fig. 1 ). As an illustration, it has been elucidated that m6A modification has a substantial influence on follicular development and oocyte growth. Based on RNA-seq and Me RIP-seq results, researchers discovered that Itsn2 is targeted for m6A modification by METTL3, thereby enhancing its stability and then affecting the oocyte meiotic process [ 12 , 13 ]. Itsn2 is a critical adapter protein that has a significant role in regulating oocyte meiotic resumption [ 14 ]. The presence of m6A modification in ovarian tissue of individuals diagnosed with polycystic ovary syndrome (PCOS) is dysregulated, which disrupts follicular development and growth, ultimately leading to ovarian dysfunction and the pathogenesis of PCOS. This process involves the alteration of key signaling pathways, including PI3K/Akt and mTOR, which play critical roles in regulating ovarian function and folliculogenesis [ 15 ]. m6A regulators appear to be involved in reproductive aging. Sun et al. evaluated the levels of expression of FTO and m6A methylation levels within various germ cells and found that FTO expression gradually decreased but m6A showed an increasing trend during the aging process [ 16 ]. In order to ascertain the precise mechanism at play, additional research is required. Furthermore, pertinent investigations have suggested that m6A additionally contributes to mechanisms associated with gynecological cancer [ 17 – 19 ]. m6A modification regulates tumor growth and dissemination by regulating the expression levels of oncogenes and tumor suppressor genes. Consequently, clinical research may leverage m6A modification as a diagnostic and prognostic biomarker for various diseases affecting the female reproductive system, enabling personalized diagnosis and treatment through the identification of potential therapeutic targets. m6A modification is increasingly recognized for its significant role in female reproductive health. However, further investigation is essential to more comprehensively understand the correlation between m6A modification and female reproductive system function, as well as the deeper mechanisms involved. Fig. 1 The composition, biological functions, and potential roles of m6A modifications in the female reproductive system. m6A writers (METTL3, METTL14, WTAP, RBM15/15B, VIRMA), m6A erasers (ALKBH5 and FTO), and m6A readers (YTH family protein and hnRNPs protein) are the primary regulators of the m6A modification. m6A methylation modification is involved in the regulation of alternative splicing, nuclear export, degradation, translation, and RNA stability. In the process of female reproduction, m6A RNA modification is also essential for oogenesis, ovulation, and embryonic development. m6A writers (METTL3, METTL14, WTAP, RBM15/15B, VIRMA), m6A erasers (ALKBH5 and FTO), and m6A readers (YTH family protein and hnRNPs protein) are the primary regulators of the m6A modification. m6A methylation modification is involved in the regulation of alternative splicing, nuclear export, degradation, translation, and RNA stability. In the process of female reproduction, m6A RNA modification is also essential for oogenesis, ovulation, and embryonic development. This manuscript presents an exhaustive review of m6A regulators and their biological function-related mechanisms, as well as the progress made in detecting m6A. Our emphasis is on the pivotal role of m6A modification in shaping and regulating the maternal-fetal immune microenvironment, as well as influencing the treatment and prognosis of obstetrics and gynecology-related diseases. We provide obstetricians and gynecologists with a new perspective to understand associated diseases more thoroughly, which will improve their future comprehension of these conditions.

The function of m6A modification in folliculogenesis and oocyte maturation is a relatively active area of recent research. During the embryonic stage, primary oocytes within primordial follicles undergo and remain in meiotic prophase I. In preparation for the initial embryonic development, oocytes progressively increase in size and accumulate substantial quantities of mRNA and protein. Oocytes enter metaphase I from meiotic prophase I during follicular maturation, resulting in the formation of secondary oocytes and polar bodies. Secondary oocytes undergo meiotic second division, remain in metaphase II, and complete development prior to ovulation and fertilization [ 197 ]. The m6A modification controls the maturation process of oocytes, influences both the stability and translation efficiency of mRNA, regulates the expression of related genes through multiple biological mechanisms involved in precise epigenetic regulation in oocytes. METTL3 expression is elevated during oogenesis. In a study, siRNA was employed to knockdown Mettl3 in oocytes of the mouse germinalvesicle stage. This caused abnormal spindles, slowed down meiotic progression, reduced the efficacy of mRNA translation, impacted mRNA degradation, and halted oocyte development [ 198 ]. Supporting this conclusion, an additional investigation discovered that METTL3 mutations impeded the initial stages of oocyte development and resulted in a substantially lower percentage of fully developed follicles than controls. Intersectin 2 (ITSN2) is a multifunctional protein that is involved in the process of meiotic resumption in oocytes [ 14 ]. METTL3 identifies and attaches to ITSN2 and carries out m6A alteration, which can increase its durability and facilitate oocyte development. Specific Mettl3 knockout in mouse oocytes causes meiotic maturation failure [ 13 ]. Also, the development of oocytes is halted and adult females become less fertile when mettl3 mutations are detected in zebrafish. This could be due to the global decrease in m6A levels and the blockage of critical genes that are necessary for the production of hormones and gonadotropins [ 199 ]. A study conducted on oocytes from pigs revealed that the methylation of m6A by METTL3 and WTAP has the potential to influence the maturation of oocytes and the growth of embryos [ 200 ]. The reading proteins YTHDC1 and YTHDC2 are required for oocyte maturation. Seth D. Kasowitz et al. engaged in a mouse study in which the inactivation of YTHDC1 led to mRNA defects in alternative splicing in mouse oocytes. The production of extensive variable polyadenylation altered the 3ʹUTR length, thereby hindering oogenesis [ 201 ]. YTHDC2-deficient female mice have small ovaries and lack fertility [ 202 ]. YTHDF2 regulates the degradation of maternal mRNA during MII [ 203 ]. Knocking down YTHDF2 modifies the amount of transcription of genes that affect oocyte development, thereby affecting the quality of oocytes. In mice, the absence of YTHDF2 results in the failure of oocyte maturation and female-specific infertility. KIAA1429 controls the alternative splicing of genes involved in oocyte maturation. Conditional knockout mice display Kiaa1429 in their oocytes, resulting in female mice becoming infertile [ 204 ]. The IGF2BPs family has a role in oocyte maturation by engaging in the m6A methylation process of RNA and enhancing mRNA stability [ 13 ]. Additionally, a transcriptome-wide investigation of chicken follicles by Yu et al. indicates that the follicle selection process may be influenced by m6A modification [ 205 ]. Embryonic development commences with fertilization, during which the zygote exhibits a transcriptionally quiescent state. Following this, the maternal-to-zygote transition (MZT) occurs, which involves the activation of the zygote genome (ZGA) and the elimination of maternal storage (RNA and DNA) [ 206 , 207 ]. The importance of RNA m6A modification in the development of mammalian embryos has been increasingly recognized in a variety of studies [ 208 ]. It has been reported that the degradation of maternal mRNA is impeded by the loss of Mettl3 in mouse oocytes, which in turn affects embryonic developmental progression by impeding MZT and zygotic genome activation [ 198 , 209 ]. m6A methylation can also influence embryonic development by modulating the stability of mammalian embryonic stem cells (mESC). For example, the absence of Mettl3 results in the loss of the self-renewal and differentiation capabilities of rodent embryonic stem cells [ 210 , 211 ]. Relevant demonstrated that the Mettl3 gene deletion in mammals results in embryonic mortality [ 212 , 213 ]. Mettl14 deficiency substantially delays early embryonic development and results in embryonic death, primarily by obstructing the process of ectodermal cell differentiation to maturation [ 214 ]. Furthermore, a study conducted by Liu et al., which involved the construction of an embryonic mouse model lacking Mettl16, discovered that the absence of Mettl16 resulted in a reduction in the mRNA levels of its methylation target Methionine adenosyltransferase 2 A (MAT2A) and the obstruction of embryonic development. This finding underscores the essential role of Mettl16 during the initial phases of embryonic development [ 29 ]. Researchers have also shown that the recently discovered writing protein Mettl5 affects embryogenesis by participating in the m6A modification of rRNA and regulating pluripotency in mouse embryonic stem cells (mESC) [ 123 ]. As mentioned above, YTHDC1 not only regulates oogenesis but also participates in the self-renewal and differentiation processes of mouse embryonic stem cells, which affects embryonic development [ 201 ]. Studies have shown that YTHDC2-knockout mice survive, but their adult counterparts are infertile [ 202 ]. Suppression of the IGF2BP2 protein results in the halting of mouse embryos at the 2-cell stage and hinders the advancement of early embryonic development [ 215 ]. A study discovered that the inhibition of YTHDF2 in goat embryonic cells resulted in the prevention of maternal mRNA degradation and impaired zygotic genome activation. It was hypothesized that YTHDF2 influences mRNA clearance by controlling the expression of adenosine deaminase and mRNA decapping enzyme [ 216 ]. Studies using mouse and zebrafish have demonstrated that the deletion of the maternal YTHDF2 gene significantly hinders the development of embryos [ 217 , 218 ]. Furthermore, the demethylase ALKBH5 primarily controls the development of the male testes [ 219 ]. FTO in mESC is responsible for the demethylation modification of long interspersed element 1 (LINE1) RNA, which has an impact on embryonic development, growth, and differentiation of embryonic stem cells [ 220 ]. To understand the complex mechanisms of gynecology-related diseases, it is essential to conduct a more thorough investigation of the molecular mechanisms of the connection between the m6A modification and embryonic development. The placenta acts as a bridge between the mother and the baby, performing tasks like immunological modulation, nutrition exchange, and stress response. It also plays an essential role in preserving pregnancy and the growth of the fetus [ 221 , 222 ]. Placental cells, particularly trophoblast cells, are highly proliferative and invasive. The modulation of the maternal immune system and gene expression is facilitated by their involvement in numerous mechanisms, which are designed to ensure the seamless implantation and development of the embryo in utero [ 223 , 224 ]. Furthermore, the placenta, functioning as a physiological neoplasm, is connected to cancer through multiple processes [ 225 ]. The majority of m6A modification sites are situated in introns of human placental tissue and are enriched near stop codons [ 208 , 226 , 227 ]. The methylation modification of m6A significantly influences the biological function of placental cells. By increasing the stability of placental villous trophoblast cells, the m6A methylation of MYLK mRNA by methyllase-METTL3 can affect their invasiveness. Additionally, it is implicated in the regulation of preeclampsia [ 228 ]. YTHDC1 is involved in the m6A methylation modification of circMPP1, which leads to a decrease in its expression and the inhibition of placental function. This process is regulated by both the NF-κB and MAPK3 signaling pathways [ 229 ]. Through an analysis of the m6A modification levels at the 5ʹ-UTR of placental mRNA in infants with varying birth weights, one study suggested that m6A modification may regulate placental function and influence fetal growth by participating in translational regulation [ 208 ]. Through the development of a BaP-exposed mouse model, Wang et al. discovered that lnc-HZ14 induces early abortion and promotes placental trophoblast pyroptosis by participating in and increasing the METTL3-mediated m6A modification of pyridine domain-containing 3 inflammasome (NLRP3) mRNA in the NOD-like receptor (NLR) family [ 230 ]. The demethylase ALKBH5 is an important regulator of placental development. Knocking down ALKBH5 can promote trophoblast invasiveness and result in recurrent miscarriage, as it can modify human trophoblast invasiveness by regulating CYR61 mRNA stability [ 231 ]. Another study also verified the involvement of ALKBH5 in the progress of preeclampsia by modulating the m6A methylation modification of PPARG mRNA [ 232 ]. Placental dysplasia-related proteins and targets are important for the early diagnosis and management of gynecological diseases. Nevertheless, there are limited relevant studies, and their specific mechanisms require further investigation. The maternal-fetal microenvironment is a complex biological interface between the mother and fetus. Its main role is to support the embryo’s growth and development while protecting it from harmful substances and pathogens. Furthermore, the occurrence of related diseases is closely correlated with alterations in the maternal-fetal interface microenvironment [ 233 ]. Germ stem cells are implicated in mechanisms related to immune tolerance and fetal development in the maternal-fetal microenvironment. The study of cancer stem cells is provided with a distinctive perspective by the similarity between the maternal-fetal microenvironment and the tumor microenvironment in certain regulatory pathways and mechanisms. The normal development of embryos is ensured by the interaction between multiple important immune cells, which is crucial in the mother and fetus’s mutual equilibrium of immunological tolerance and protection (Fig. 2 ). Cross-sectional research in these regions offer substantial support for comprehending the operation of the female reproductive system. Fig. 2 m6A modification regulates the function of immune cells in the maternal-fetal microenvironment through multiple mechanisms. A In DCs, m6A methylation regulates the translation of proteases in CD40, CD80, and lysosomes, thereby promoting DC maturation and inhibiting antigen presentation. METTL3 influences the energy metabolism of DC by regulating the expression of HIF-1 and the glycolytic gene LDHA. B by modulating SOCS family mRNA and the IL-7/JAK/STAT5 pathway, METTL3 maintains CD4 + T cell homeostasis. Additionally, it is essential for the development of Tfh cells. METTL14 deficiency results in the blocking of Treg cell differentiation. C In macrophages, METTL3 regulates the tumor microenvironment (TME), disrupts TLR4 and ERK signaling pathways, affects Irakm and Spred2 expression, and inhibits tumor progression. D m6A modification plays an important role in various developmental stages of B cells. E NK cell function is regulated by the degradation of STAT5 mRNA and the expression of SHP-2, which are regulated by YTHDF2 and METTL3, respectively. A In DCs, m6A methylation regulates the translation of proteases in CD40, CD80, and lysosomes, thereby promoting DC maturation and inhibiting antigen presentation. METTL3 influences the energy metabolism of DC by regulating the expression of HIF-1 and the glycolytic gene LDHA. B by modulating SOCS family mRNA and the IL-7/JAK/STAT5 pathway, METTL3 maintains CD4 + T cell homeostasis. Additionally, it is essential for the development of Tfh cells. METTL14 deficiency results in the blocking of Treg cell differentiation. C In macrophages, METTL3 regulates the tumor microenvironment (TME), disrupts TLR4 and ERK signaling pathways, affects Irakm and Spred2 expression, and inhibits tumor progression. D m6A modification plays an important role in various developmental stages of B cells. E NK cell function is regulated by the degradation of STAT5 mRNA and the expression of SHP-2, which are regulated by YTHDF2 and METTL3, respectively. Female germline stem cells (FGSCs) are a kind of stem cell that are found in the female reproductive system of mammals. They possess the ability to self-renew and develop into fully mature oocytes [ 234 , 235 ]. The relationship between FGSC and m6A modification has garnered a growing amount of attention in recent years. Zhao et al. performed a comparative investigation of the m6A methylation levels of mRNAs in female mouse germline stem cells and thioguanine and ubarine-resistant (STO) cells using MeRIP-seq. They discovered that the former had significantly higher overall m6A levels than the latter. Subsequent investigations indicated that the proliferation process of FGSC was influenced by the reading protein YTHDF1, and the self-renewal capacity of FGSC was substantially reduced by a specific knockdown of YTHDF1 [ 236 ]. In addition, correlational research has suggested that the m6A modification of non-coding RNAs is associated with FGSC. For instance, the nuclear export progression of circGFRα1 is influenced by the m6A modification mediated by methylase METTL14, which in turn regulates GFRα1 expression and influences self-renewal in FGSC [ 237 ]. Currently, the specific relationship between m6A modifications and FGSCs is being investigated; however, it is conceivable that m6A modifications may be crucial in the preservation of the self-renewal and differentiation processes of FGSCs. We can anticipate a more comprehensive comprehension of this field as science and technology continue to advance and research continues to deepen. Cancer stem cells (CSC) are present in various of tumor types and possess stem cell characteristics. They are vital in tumor progression, recurrence, drug resistance, and metastasis of tumors [ 238 – 240 ]. The invasiveness of the placenta is somewhat similar to the mechanisms associated with CSCs, which also suggests a potential role for the maternal-fetal microenvironment in the development of tumors. Numerous studies have documented a correlation of m6A and tumor resistance, tumor epithelial-mesenchymal transition (EMT), and self-renewal and differentiation of cancer stem cells [ 241 – 243 ]. Currently, there has been a growing interest in the close correlation between CSC and m6A modification. Numerous malignancies including breast cancer [ 244 ], lung cancer [ 245 ], cutaneous squamous cell carcinoma [ 246 ], acute leukemia [ 247 ], and colon cancer [ 111 ], have been disclosed to play critical functions in m6A modification. Gradually, studies that investigate the relationship between gynecological malignancies and CSC are also being conducted. A study of cisplatin-resistant ovarian cancer cell lines discovered that YTHDF1 was capable of resisting ovarian cancer cells by improving their CSC-like characteristics and promoting tumor progression by binding to m6A-modified three-part motif protein 29 (TRIM 29) and enhancing its translational efficiency [ 248 ]. In cervical cancer, overexpression of TRIM 29 also has a carcinogenic effect, but more researches are required to determine the complete mechanism [ 249 ]. Based on an investigation conducted by Chen et al., hypoxia induces the demethylase ALKBH5, which in turn regulates the m6A methylation of the transcription factor SOX2 mRNA and promotes the properties of endometrial cancer stem cells by reducing its methylation level. Hypoxia-inducible factor downregulated the level of ALKBH5 protein, which in turn inhibited the tumorigenicity of CSCs, thereby confirming the aforementioned conclusion [ 250 ]. A comprehensive understanding of the characteristics and mechanisms related to CSC could enhance patient survival, reduce tumor recurrence and metastasis, and contribute to a more effective clinical battle against cancer. m6A modification not only influences the biological behavior of tumor cells but also regulates key processes within the tumor microenvironment (TME), including the hypoxic response, metabolic reprogramming, cell cycle regulation, and immune cell function. In the immune microenvironment, tumor cells depend on glycolysis to sustain their energy supply [ 251 ]. A study by Li et al. employed Mettl3-knockdown cervical cancer cell lines (HeLa and SiHa) alongside the human normal cervical epithelial cell line ECT1/E6E7 for in vivo and in vitro assays. The results indicated that YTHDF1 and IGF2BP3-dependent m6A methylation positively regulates glycolysis in cancer cells, thereby promoting tumor growth and progress by enhancing the stability and translation efficiency of PDK4 mRNA [ 252 ]. Additionally, another study unveiled that METTL3 regulates CDC25B translation through m6A modification-dependent YTHDF1. This regulation was demonstrated through a comprehensive approach, including in vitro cervical cancer cell cycle synchronization, m6A-seq analysis, in vitro cell proliferation assays, and in vivo nude mouse tumor formation experiments, ultimately promoting cell cycle progression [ 253 ]. These findings highlight that m6A modification-related mechanisms hold promise as potential therapeutic targets for cancer in the future. Dendritic cells (DCs) are antigen-presenting cells (APCs) which perform vital immunoregulatory functions in the maternal-fetal microenvironment and are instrumental in the emergence and development of tumors [ 254 , 255 ]. Krey et al. developed a transgenic mouse model of DC depletion and discovered that DC deficiency prevented the embryo from implanting and resulted in aberrant vascular development in the uterine decidua. This affected the process of placenta development and the subsequent pregnancy [ 256 ]. In the past few years, m6A modification and DCs’ role in the immune microenvironment have gained increasing attention. As early as 2005, researchers proposed that the innate immune response process could be influenced by the m6A modification of RNA, which could reduce DC-mediated Toll-like receptor (TLR) expression [ 257 ]. Wang et al. discovered that the methylase Mettl3-mediated m6A modification may boost the expression of associated immune costimulators, increase their translational efficiency, activate DCs, and encourage the initiation of T cells. The TLR4/NF-κB signaling pathway is activated during this process, which results in the production of cytokines. Mettl3 knockdown then impedes this process, which impacts the normal function and maturation processes of DCs [ 258 ]. The YTHDF1 reading protein is responsible for the regulation of lysosomal proteases and the facilitation of tumor immune escape. YTHDF1 reduction enhances the capacity of DCs to present tumor antigen by decreasing its antigen consumption [ 259 ]. The putative function of YTHDF2 as a tumor immunosuppressive factor is reflected in the mechanism by which it recognizes and binds the m6A modification site of lnc-Dpf3 in DCs, thereby inhibiting DC migration [ 260 ]. To summarize, targeting m6A in DCs has great promise for cancer immunotherapy. Furthermore, the association between DC and m6A modification in obstetrics and gynecology is poorly researched, which underscores the need for additional clarification. Uterine natural killer cells (uNK cells) are a distinct type of immune cell that are present on the endometrium. They are collectively responsible for the preservation of immune homeostasis at the maternal-fetal interface. Former research has shown that the development of the placenta is contingent upon the presence of uNK cells. [ 261 ], the growth of the fetus [ 262 ], the modulation of inflammation and the immune system [ 263 ], and the mechanisms related to tumors [ 264 ]. Decidual NK (dNK) cells represent a specific subtype of uNK cell that are predominant in the early maternal-fetal interface of humans [ 265 , 266 ]. dNK cells also play a critical role in keeping maternal-fetal microenvironment homeostasis. The significance of m6A modification in modulating the activity of NK cells biological function has steadily become an increasingly hot topic, and the interaction between the two in gynecological diseases is also a developing research area. It has been reported that the process of NK cell maturation is facilitated by the m6A modification mediated by the reading protein YTHDF2. The antitumor properties of NK cells were subsequently inhibited by the specific knockdown of YTHDF2 [ 264 , 267 ]. The function of METTL3-related m6A modification in regulating NK cell killing activity has also been confirmed [ 268 ]. Furthermore, a study conducted a bioinformatics analysis of the m6A target gene cell division cycle 42 effector protein (CDC42EP3) in ovarian cancer and discovered that its down-regulation was associated with NK cell infiltration and the promotion of ovarian cancer progression. This identified a potential association between NK cells and m6A modification in ovarian cancer [ 269 ]. In contrast, demethylase FTO has an adverse impact on NK cells, and the specific reduction of FTO results in increased NK cell activation and a decreased risk of melanoma progression [ 270 ]. The diagnosis and treatment of gynecological diseases is also likely to be influenced by the specific mechanism of m6A modification in NK cells. Therefore, it is critical to have a comprehensive understanding about this mechanism. Decidual macrophages are responsible for the primary maintenance of immune tolerance at the maternal-fetal interface during pregnancy by secreting anti-inflammatory cytokines, including IL-10 and CCL2, which counteract the maternal immune system’s attack on the fetus [ 271 ]. The critical function of macrophages in immune regulation [ 272 , 273 ], trophoblast development [ 274 ], fetal growth [ 275 ], and tumorigenesis [ 276 ] has been showed in previous studies. The m6A modification has the capacity to regulate the polarization status (M1 and M2 macrophages) and biological function of macrophages by modulating gene expression mechanisms [ 277 ]. Several investigations have confirmed that the methylase METTL3-mediated m6A modification may increase the expression of the transcription factor STAT1, thereby positively influencing M1 macrophage polarization while negatively affecting M2 macrophage polarization [ 278 , 279 ]. YTHDF2 is also involved in the regulation of m6A modification of STAT1 mRNA and the promotion of its degradation, which in turn promotes the polarization of M1 macrophages. This process is accomplished by interacting with the RNA-binding motif 4 (RBM4) [ 280 ]. Nevertheless, a study discovered that lactate could stimulate the production of Mettl3-mediated m6A modification, which then positively regulated the polarization of M2 macrophages and resulted in the invasion of endometriosis [ 281 ]. In addition, the interaction between m6A modification and tumor-associated macrophages (TAM) is becoming increasingly significant in the modulation of tumor immunity and drug resistance. For instance, ALKBH5 has the potential to influence the homeostasis of the tumor microenvironment by modulating macrophage polarization and function. Jiang et al. conducted an in vitro simulation of the tumor microenvironment by cultivating ovarian cancer cells and M2 macrophages. They discovered that both demethylase ALKBH5 and TLR4 expression were increased, confirming that ALKBH5-mediated m6A demethylation modification activates the NF-κB pathway, which promotes the invasiveness of ovarian cancer [ 282 ]. Furthermore, the significance of the interaction between TAM and the ovarian cancer microenvironment has been elucidated in related studies, which are intended to investigate resistance-associated targets and recurrence markers [ 283 ]. In cervical cancer, a study suggested that the glycolytic process is targeted, programmed cell death protein 1 (PD-1) expression is facilitated, and macrophage phagocytic function is inhibited by high expression of the m6A regulator METTL14, which accelerates cancer progression [ 284 ]. Therefore, the disclosure of the comprehensive effect of m6A modification on macrophage function could enhance comprehension of the role of macrophages in tumor microenvironment and gynecology-related immune responses, thereby facilitating the development of immunotherapeutic strategies that target m6A modification. The body’s immune balance is maintained by the synergistic action of various subsets of T cells, which are critical factors of the adaptive immune system, in recognizing and responding to pathogens and tumor cells [ 285 ]. m6A modification has demonstrated a significant role in the maternal-fetal interface by modulating T cell development, differentiation, and function [ 286 ]. Li et al. identified that the methylase METTL3-mediated m6A methylation was capable of targeting the IL-7/STAT5/SOCS pathway and influencing mRNA degradation processes, thereby modulating the proliferation and differentiation of CD4 + T cells [ 287 ]. Also, this post-transcriptional regulation, which is activated by METTL3, positively influences the differentiation of T follicular helper (Tfh) cells [ 288 ]. Regulation T (Treg) cells are induced at the maternal-fetal interface to safeguard the fetus from immune rejection and are also closely linked to recurrent miscarriage and infertility [ 289 , 290 ]. A study conducted by Tong et al. discovered that Mettl3 KO mice exhibited infertility as a result of autoimmune defects, and they specifically lost the suppressive function of Tregs in comparison to their WT littermates. This result also serves as confirmation of the essential regulatory function that METTL3 serves in the preservation of the immunosuppressive function of Treg cells [ 291 ]. In ovarian cancer, the C3a anaphylatoxin chemotactic receptor (C3AR1) is associated with the activation of T cells and the penetration of immune cells by mediating m6A modification in OC cells, which results in the development of ovarian cancer [ 292 ]. An in-depth examination of the molecular mechanisms involved in T cell modification with m6A could aid in the comprehension of the intricate regulatory network of the immune system and potentially offer new strategies and targets for the medical management of maternal-fetal-related diseases. B cells are mainly involved in humoral immunity, which involves the production of specific antibodies to neutralize pathogens and functions by recognizing antigens [ 293 ]. Currently, there is a limited number studies examining the correlation between B cells and the maternal-fetal immune microenvironment. According to reports, trophoblast glycoprotein (TPG) is capable of binding B cell receptors and inhibiting their activation, which is crucial for the promotion of maternal-embryonic immune tolerance and the maintenance of normal fetal development [ 294 ]. Additionally, a study found that decidual B cells can prevent spontaneous preterm birth by interfering with the PIBF1 pathway, which is regulated by interleukin 33 (IL-33) [ 295 ]. Related research has indicated that m6A modification may be a critical factor in the early progress of B cells. For instance, METTL14-mediated m6A methylation is involved in B cell maturation, whereas YTHDF2 reduces interleukin-7 (IL-7)-induced pro-B cell proliferation by binding to m6A modification sites and degrading specific mRNA transcripts, thereby influencing early B cell transformation processes [ 296 ]. This process is not regulated by YTHDF1 [ 296 ]. Furthermore, the development and prognosis of acute lymphoblastic leukemia [ 297 ], human glioma cells [ 298 ], and other conditions may be influenced by aberrant methylation modification of m6A in B cells. A study conducted a biological information analysis to screen m6A-related lncRNA prognostic genes in patients with endometrial cancer of the corpus uteri (UCEC). The results indicated that B-cell immune infiltration scores were elevated in the high-risk group than in the low-risk group of the disease, suggesting a possible role for B cells in the progression and prognosis of UCEC [ 299 ]. Currently, the investigation of B cells in epigenetic modifications is in its infancy, necessitating the subsequent undertaking of more comprehensive studies on gynecology-related diseases that are founded on the interaction between m6A and B cells. Female reproductive hormones are indispensable for the modulation of reproductive system function, the maintenance of reproductive health, and the regulation of the female reproductive cycle [ 300 ]. The biological roles of the female reproductive system and the development of related diseases have progressively received attention to the regulation of reproductive hormones by m6A modification. However, there are limited studies in this field. Previous sections have indicated that the suppression of METTL3 has the capacity to modulate the expression of genes that are essential for the synthesis of sex hormones, thereby contributing to oocyte development [ 199 ]. Gonadotropin-releasing hormone (GnRH) is a decapeptide hormone secreted by the hypothalamus that affects the progression and function of the female gonad by regulating gonadotropin (LH and FSH) secretion from the anterior pituitary gland. Pulsatile release of GnRH is indispensable for the preservation of typical reproductive function [ 301 , 302 ]. A study discovered that the demethylase FTO enhances the stability of Foxp2 mRNA and mediates m6A demethylation, thereby promoting gonadotropin synthesis and secretion by up-regulating the cAMP/PKA signaling pathway [ 303 ]. According to a study accompanied by Wan et al., the methylation modification of m6A by METTL3 can be instrumental in the regulation of the mRNA stability of the estrogen response genes Elf3 and Celsr2 and the maintenance of the expression level of the progesterone receptor PR. This modification is vital for the regulation of intrauterine estrogen and progesterone signaling. Knockdown of METTL3 leads to infertility [ 304 ]. Another study also confirmed that METTL3-mediated m6A modulates the process of mbryo implantation by affecting progesterone signaling through the regulation of the progesterone receptor gene (Pgr) mRNA translation process [ 305 ]. Additionally, Mettl14 is involved in the modulation of embryo implantation through a m6A modification-dependent pathway, a process that involves immune-related mechanisms and estrogen receptor α (ERα) signal transduction pathways [ 306 ]. Xue et al. also confirmed that FTO-mediated m6A demethylation is involved in the development of polycystic ovary syndrome by modulating the androgen receptor/protein kinase B (AR/AKT) pathway, which is responsible for affecting androgen levels in granulosa cells and follicular fluid [ 307 ]. A thorough investigation of the precise function of m6A modification in the synthesis and secretion of female reproductive hormones can facilitate the exploration of the pathogenesis of reproductive system diseases and the development of innovative strategies for their diagnosis and treatment.